Retension Pharmaceuticals (RTSN) sets terms for $39.6 million Nasdaq IPO
As seen on the 24/7 Wall St. homepage on October 5, 2026.
Retension sets $11-$13 range for $39.6 million Nasdaq IPO
Retension Pharmaceuticals just put terms on its Nasdaq listing: 3.3 million shares at $11 to $13, about $39.6 million at the midpoint. Leerink, Guggenheim and Oppenheimer are running the book, a heavyweight lineup for a deal this size. Pricing is the next event to watch.
Continue ReadingShow less
Retension Pharmaceuticals has set terms for a Nasdaq initial public offering that would raise roughly $39.6 million at the midpoint, putting it in small-cap biotech territory.
Leerink Partners, Guggenheim Securities, and Oppenheimer are jointly running the book, bringing senior institutional distribution reach to a relatively compact offering.
The pricing decision is the next event, and where the deal prices against the $11 to $13 range is the earliest read on institutional demand.
The filing was made public on October 5, 2026, with full terms in the SEC filing for investors reviewing the prospectus directly.